A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein. By binding to BCL-2
protein, TQB3909 releases Pro apoptotic proteins such as BCL-2-Anatagonist/Killer 1(BAK),
BCL-2 associated X (BAX) protein and BCL-2 associated death (BAD) protein, promotes the
release of cytochrome c from mitochondria, phosphatidylserine eversion, stimulates caspase 3
/ 7 activity and caspase 3 / 9 cleavage, and induces apoptosis.